Literature DB >> 8377750

Fetal effects.

C A Chiriboga1.   

Abstract

The adverse effects of fetal drug exposures are well documented. Evidence for FAS, impaired intrauterine growth, birth defects, and mental retardation related to alcohol is compelling; evidence for alcohol-induced adverse behaviors and impaired speech is tenuous. Teratogenic, cognitive, or behavioral effects associated with prenatal exposure to marijuana, cigarettes, cocaine, or opiates have not been well established. The most convincing finding related to prenatal exposure to such substances is IUGR. Impaired fetal growth, especially of brain, may indirectly mediate drug effects on cognition. The abnormal neonatal neuro-behaviors described herein have no apparent impact on subsequent development. The development of opiate-exposed children, particularly those with withdrawal symptoms, however, appears to be more vulnerable to the adverse effects of an impoverished environment.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8377750

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  5 in total

1.  Sleep problems in children with prenatal substance exposure: the Maternal Lifestyle study.

Authors:  Kristen C Stone; Linda L LaGasse; Barry M Lester; Seetha Shankaran; Henrietta S Bada; Charles R Bauer; Jane A Hammond
Journal:  Arch Pediatr Adolesc Med       Date:  2010-05

2.  Hyperphagia in neonates withdrawing from methadone.

Authors:  A Martinez; B Kastner; H W Taeusch
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1999-05       Impact factor: 5.747

3.  Longitudinal study of maternal report of sleep problems in children with prenatal exposure to cocaine and other drugs.

Authors:  Kristen C Stone; Pamela C High; Cynthia L Miller-Loncar; Linda L Lagasse; Barry M Lester
Journal:  Behav Sleep Med       Date:  2009       Impact factor: 2.964

4.  Neonatal neurobehavior effects following buprenorphine versus methadone exposure.

Authors:  Mara G Coyle; Amy L Salisbury; Barry M Lester; Hendrée E Jones; Hai Lin; Klaudia Graf-Rohrmeister; Gabriele Fischer
Journal:  Addiction       Date:  2012-11       Impact factor: 6.526

Review 5.  Methods to identify and characterize developmental neurotoxicity for human health risk assessment. III: pharmacokinetic and pharmacodynamic considerations.

Authors:  D C Dorman; S L Allen; J Z Byczkowski; L Claudio; J E Fisher; J W Fisher; G J Harry; A A Li; S L Makris; S Padilla; L G Sultatos; B E Mileson
Journal:  Environ Health Perspect       Date:  2001-03       Impact factor: 9.031

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.